Kris Joshi Takes the Helm as CEO of Norstella
Kris Joshi has been named CEO of Norstella, a New York-based pharmaceutical solutions provider and parent company of Generics Bulletin. With over 25 years of leadership experience spanning technology and healthcare, Joshi arrives from UnitedHealth Group’s Optum. His background includes senior roles at IBM, Oracle, and Change Healthcare, equipping him to guide Norstella through its next phase.
Key Points for Executives
- Kris Joshi steps in as CEO; Mike Gallup remains as chairman after five years leading the company.
- Joshi is prioritizing an “AI First Approach” across Norstella’s products and services.
- Growth through mergers and acquisitions (M&A) will continue alongside organic expansion and strategic partnerships.
Driving an AI-First Strategy
Joshi is focusing on integrating artificial intelligence deeply within Norstella’s operations. In his words, the company’s future lies in leveraging data with AI across nearly every aspect of the business. Norstella’s offerings range from news and insights to data intelligence and consulting, all aimed at streamlining access to lifesaving medicines.
Joshi aims to make AI adoption a company-wide priority, emphasizing that the vision extends beyond isolated projects. By harnessing proprietary data and integrating multiple sources, Norstella plans to make complex data accessible without requiring advanced data science expertise.
Joshi: “It’s about making data user-friendly so that you don’t need a data science degree to get good answers.”
Focus on Harmonization and Collaboration
Pharmaceutical companies face increasing challenges from geopolitical and regulatory pressures. While Joshi acknowledges Norstella cannot resolve every issue, he sees a clear opportunity to help clients reduce financial and commercial risks. The key lies in enhancing efficiency and patient engagement through improved data use.
Joshi highlights the value of integrating Norstella’s product portfolio more closely. Individual products perform well on their own, but combined they can deliver greater impact and value.
Growth Through M&A and Partnerships
Norstella expanded significantly in 2022 by acquiring Citeline, adding clinical, regulatory, and news intelligence tools like Pharmaprojects, Trialtrove, Biomedtracker, Generics Bulletin, Scrip, and Pink Sheet. This complements other brands such as Evaluate, MMIT, Panalgo, and The Dedham Group.
Joshi plans to pursue growth aggressively in each business area, aiming to deepen customer engagement and product usage. While M&A remains an important growth driver, he also stresses the importance of organic growth and forming strategic partnerships to enhance Norstella’s platform.
Joshi: “We will continue exploring M&A opportunities and expand strategic partnerships to increase value for both customers and partners.”
Experience at the Intersection of Healthcare and Technology
With a career spanning 25 years in healthcare technology, Joshi understands the scale of challenges facing the industry. He believes technical solutions are critical to improving healthcare outcomes and sees Norstella positioned to deliver long-term value through a differentiated platform.
Executives interested in AI’s practical applications in healthcare and business growth strategies may find Joshi’s approach noteworthy. His emphasis on data accessibility, cross-product collaboration, and balanced growth strategies provides a clear roadmap for driving innovation while managing risk.
For those looking to deepen their understanding of AI’s role in business leadership and healthcare, exploring relevant AI training resources can provide valuable insights and skills.
Your membership also unlocks:
